Altria
MO
$78.03
+1.67%
Altria Group is the dominant U.S. tobacco company, operating Philip Morris USA (maker of Marlboro, the leading U.S. cigarette brand with roughly 40% share), U.S. Smokeless Tobacco, John Middleton cigars, and a portfolio of reduced-risk ventures including Njoy vaping, the On nicotine pouch brand, and a heated-tobacco joint venture with Japan Tobacco, alongside an 8% stake in AB InBev and a 41% interest in Cronos. Its competitive identity is that of a cash-generative, high-margin incumbent defending a structurally declining category while attempting to build a smoke-free future — a classic "melting ice cube" franchise whose value rests on pricing power and capital return rather than volume growth. The current investor debate centers on whether Altria's roughly 7% dividend yield and 57-year dividend-growth streak can be sustained against persistent cigarette volume declines, a payout ratio hovering near 100% of earnings, and underwhelming traction in smoke-free products. Recent headlines capture this tension: a Q2 2026 earnings miss that sent shares sharply lower on July 30, followed by a dividend increase of nearly 5% in September that reinforced the income thesis while raising questions about cash-flow coverage.…
MO
Altria
$78.03
Related headlines
MO 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Altria's 12-month outlook, with a consensus price target around $72.55 and implied upside of -7.0% versus the current price.
Average Target
$72.55
0 analysts
Implied Upside
-7.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$58 - $85
Analyst target range
Bulls vs Bears: MO Investment Factors
The bull case rests on hard, verifiable numbers: a 7.20% yield, 12.67x forward earnings, an 8.6% FCF yield, and a 0.46 beta that has delivered 29.7% YTD returns versus 11.5% for the index. The bear case rests on the sustainability of that payout — a 100.2% payout ratio against structurally declining cigarette volumes and a smoke-free portfolio that has not yet proven it can replace them. On balance the evidence currently favors the bulls for income-focused investors, because cash flow ($8.30 billion TTM) still covers the dividend and the valuation embeds very little optimism. The single most important tension is dividend coverage: if the payout ratio stays near 100% while volumes keep falling, the 57-year streak becomes a liability rather than an asset; if pricing power keeps FCF stable, the stock is materially undervalued.
Bullish
- 7.2% yield with 57-year streak: Altria pays a 7.20% dividend yield, roughly 5.5x the S&P 500's typical yield, and just raised the quarterly payout by nearly 5% in September 2026, extending a 57-year dividend-growth streak. For income investors this is the single most concrete and verifiable element of the thesis.
- Deep value multiple at 12.7x forward: The stock trades at 12.67x forward EPS of $6.67 and 14.03x trailing earnings, with a price-to-cash-flow of just 10.4x and EV/EBITDA of 10.9x. These are low absolute multiples for a business generating a 59.8% operating margin and 34.5% net margin.
- Exceptional profitability and cash generation: Gross margin is 72.2%, operating margin 59.8%, and ROA 23.8%, while trailing free cash flow is $8.30 billion against a $96.7 billion market cap — a roughly 8.6% FCF yield. That cash flow is what funds both the dividend and buybacks.
- Defensive low-beta profile outperforming: Beta of 0.461 means the stock moves less than half as much as the market, and it has returned +29.7% YTD versus +11.5% for the S&P 500 (18.2 points of relative strength). In a market where the index fell 1.02% over the past month, MO rose 7.77%.
Bearish
- Payout ratio of 100% leaves no cushion: The payout ratio is 1.0019 — the dividend consumes essentially all of reported earnings, and the September raise pushed it further. Any earnings miss, like the Q2 2026 shortfall that sent shares down 9.3% on July 30 (from $74.92 to $67.94), directly threatens coverage.
- Structural cigarette volume decline: The core Philip Morris USA franchise faces persistent volume erosion, and the Q2 2026 earnings miss was explicitly tied to declining cigarette volumes. Revenue growth of 15.5% YoY in Q2 was driven by pricing and mix, not units — a model that becomes harder to sustain each year.
- Smoke-free portfolio underdelivering: Njoy vaping, On pouches, and the Japan Tobacco heated-tobacco JV have not offset cigarette declines, and multiple analyst notes flag 'smoke-free struggles' as the key long-term risk. Capital deployed into these ventures has yet to produce a visible inflection.
- Balance sheet and negative equity optics: The current ratio is 0.61, well below 1.0, indicating thin short-term liquidity, and the company carries negative book equity (P/B of -27.6, debt-to-equity of -7.34) reflecting decades of buybacks and write-downs. Interest expense of $295 million in Q2 alone consumes a meaningful slice of operating income.
MO Technical Analysis
Beta
—
—
Max Drawdown
-17.9%
Largest decline past year
52-Week Range
$55-$80
Price range past year
Annual Return
+36.6%
Cumulative gain past year
| Period | MO Return | S&P 500 |
|---|---|---|
| 1m | +15.9% | -0.9% |
| 3m | +14.2% | +1.2% |
| 6m | +4.7% | +4.9% |
| 1y | +36.6% | +11.2% |
| ytd | +36.2% | +10.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MO Fundamental Analysis
Quarterly Revenue
$6.1B
2026-06
Revenue YoY Growth
+15.5%
YoY Comparison
Gross Margin
74.9%
Latest Quarter
Free Cash Flow
$8.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MO Overvalued?
PE
14.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 5x~13x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the dividend's thin coverage. The payout ratio of 1.0019 means Altria distributes essentially 100% of earnings, leaving no retained cushion, while the current ratio of 0.61 signals limited short-term liquidity and negative book equity (P/B of -27.6) reflects a balance sheet shaped by buybacks rather than asset accumulation. Interest expense of $295 million in Q2 2026 and $258 million in Q1 consumes roughly 9-10% of operating income, and quarterly EPS has ranged from $0.63 to $1.80 over the past eight quarters due to large one-off charges, including a -$1.398 billion other-expense line in Q4 2025. Revenue is highly concentrated in U.S. combustible cigarettes, so a faster-than-expected volume decline cannot be easily offset.
Market and competitive risks are dominated by valuation compression and category disruption. At 12.67x forward earnings and 10.9x EV/EBITDA the stock is not expensive in absolute terms, but it is a value trap candidate if earnings estimates of $6.67 prove too high; the Q2 2026 miss and the 9.3% single-day drop on July 30 show how quickly sentiment can reverse. Beta of 0.461 limits macro-driven drawdowns, but it also means the stock lags in strong risk-on rallies — it underperformed the S&P 500 by 1.04 points over three months even while beating it by 18.2 points YTD. Competitive pressure from illicit disposable vapes, potential FDA menthol or nicotine-cap regulation, and the failure of Njoy and On to gain share are the specific threats that could force write-downs.
The worst-case scenario is a dividend cut or freeze triggered by a second consecutive earnings miss and accelerating volume declines. In that chain, the stock would likely retest its 52-week low of $54.70, which is 26.4% below the current $74.31 — and the analyst low target of $58.00 implies a 21.9% decline. The observed max drawdown over the period was -17.9%, so a move to the low would exceed recent historical stress. An investor buying today could realistically lose 20-26% in this adverse scenario, with the loss amplified for total-return investors if the dividend is reduced.